Cathepsins B, L and cystatin C in cyst Xuid of ovarian tumors

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 5, 2010, Pages 771-778

  Kolwijck, Eva ^a   Massuger, Leon F A G ^a   Thomas, Chris M G ^a   Span, Paul N ^a   Krasovec, Marta ^b,c   Kos, Janko ^b,c   Sweep, Fred C G J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c JO EF STEFAN INSTITUTE   (Slovenia)

Author keywords

Cathepsin; Cyst Xuid; Cystatin; Ovarian cancer; Ovarian tumor

Indexed keywords

CATHEPSIN B; CATHEPSIN L; CYSTATIN C;

ADULT; ARTICLE; BENIGN TUMOR; CONTROLLED STUDY; CORRELATION ANALYSIS; CYST FLUID; CYSTADENOCARCINOMA; CYSTADENOMA; ENDOMETRIOSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; OVARY TUMOR; PRIORITY JOURNAL; TERATOMA; TUMOR CLASSIFICATION; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; CATHEPSIN B; CATHEPSIN L; CYST FLUID; CYSTATIN C; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS;

EID: 77950478893     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-009-0716-z     Document Type: Article

References (45)

1. Aznavoorian S, Murphy AN, Stetler-Stevenson WG, Liotta LA (1993) Molecular aspects of tumor cell invasion and metastasis. Cancer 71(4):1368-1383
2. Bhuvarahamurthy V, Govindasamy S (1995) Extracellular matrix components and proteolytic enzymes in uterine cervical carcinoma. Mol Cell Biochem 144(1):35-43
3. Capo-Chichi CD, Smith ER, Yang DH, Roland IH, Vanderveer L, Cohen C, Hamilton TC, Godwin AK, Xu XX (2002) Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis. Cancer 95(8):1802-1815
4. Chauhan SC, Vinayek N, Maher DM, Bell MC, Dunham KA, Koch MD, Lio Y, Jaggi M (2007) Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multi-targeted antibody-guided therapy. J Histochem Cytochem 55(8):867-875
5. Cimerman N, Brguljan PM, Krasovec M, Suskovic S, Kos J (1999) Circadian characteristics of cathepsins B, H, L, and steWns A and B, potential markers for disease, in normal sera. Clin Chim Acta 282(1-2):211-218
6. Cimerman N, Brguljan PM, Krasovec M, Suskovic S, Kos J (2000) Twenty-four hour variations of cystatin C and total cysteine proteinase inhibitory activity in sera from healthy subjects. Clin Chim Acta 291(1):89-95
7. Cloven NG, Kyshtoobayeva A, Burger RA, Yu IR, Fruehauf JP (2004) In vitro chemoresistance and biomarker proWles are unique for histologic subtypes of epithelial ovarian cancer. Gynecol Oncol 92(1):160-166
8. Colombo N, Van GT, Parma G, Amant F, Gatta G, Sessa C, Vergote I (2006) Ovarian cancer. Crit Rev Oncol Hematol 60(2):159-179
9. Duffy MJ (1996) Proteases as prognostic markers in cancer. Clin Cancer Res 2(4):613-618
10. Feeley KM, Wells M (2001) Precursor lesions of ovarian epithelial malignancy. Histopathology 38(2):87-95
11. Gabrijelcic D, Svetic B, Spaic D, Skrk J, Budihna M, Dolenc I, Popovic T, Cotic V, Turk V (1992) Cathepsins B, H and L in human breast carcinoma. Eur J Clin Chem Clin Biochem 30(2):69-74
12. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry JP, Scolyer RA, Smith AN, Bali A, Vanden BP, Baron-Hay S, Scott C, Fink D (2006) A distinct molecular proWle associated with mucinous epithelial ovarian cancer. Br J Cancer 94(6):904-913
13. Hogdall EV, Christensen L, Kjaer SK, Blaakaer J, Kjaerbye-Thygesen A, Gayther S, Jacobs IJ, Hogdall CK (2007) CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study. Gynecol Oncol 104(3):508-515
14. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM (2008) Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 5(12):e232
15. Kos J, Smid A, Krasovec M, Svetic B, Lenarcic B, Vrhovec I, Skrk J, Turk V (1995) Lysosomal proteases cathepsins D, B, H, L and their inhibitors stefins A and B in head and neck cancer. Biol Chem Hoppe Seyler 376(7):401-405
16. Kos J, Stabuc B, Schweiger A, Krasovec M, Cimerman N, Kopitar-Jerala N, Vrhovec I (1997) Cathepsins B, H, and L and their inhibitors steWn A and cystatin C in sera of melanoma patients. Clin Cancer Res 3(10):1815-1822
17. Kos J, Nielsen HJ, Krasovec M, Christensen IJ, Cimerman N, Stephens RW, Brunner N (1998) Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer. Clin Cancer Res 4(6):1511-1516
18. Kos J, Werle B, Lah T, Brunner N (2000) Cysteine proteinases and their inhibitors in extracellular Xuids: markers for diagnosis and prognosis in cancer. Int J Biol Markers 15(1):84-89
19. Lah TT, Kokalj-Kunovar M, Kastelic L, Babnik J, Stolfa A, Rainer S, Turk V (1992) Cystatins and steWns in ascites Xuid from ovarian carcinoma. Cancer Lett 61(3):243-253
20. Lah TT, Strojnik T, Levicar N, Bervar A, Zajc I, Pilkington G, Kos J (2000) Clinical and experimental studies of cysteine cathepsins and their inhibitors in human brain tumors. Int J Biol Markers 15(1):90-93
21. Landen CN Jr, Birrer MJ, Sood AK (2008) Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 26(6):995-1005
22. Leto G, Tumminello FM, Pizzolanti G, Montalto G, Soresi M, Gebbia N (1997a) Lysosomal cathepsins B and L and SteWn A blood levels in patients with hepatocellular carcinoma and/or liver cirrhosis: potential clinical implications. Oncology 54(1):79-83
23. Leto G, Tumminello FM, Pizzolanti G, Montalto G, Soresi M, Carroccio A, Ippolito S, Gebbia N (1997b) Lysosomal aspartic and cysteine proteinases serum levels in patients with pancreatic cancer or pancreatitis. Pancreas 14(1):22-27
24. Lindeman RD, Goldman R (1986) Anatomic and physiologic age changes in the kidney. Exp Gerontol 21(4-5):379-406
25. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S (1980) Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284(5751):67-68 (Pubitemid 10098769)
26. Makarewicz R, Drewa G, Szymanski W, Skonieczna-Makarewicz I (1995) Cathepsin B in predicting the extent of the cervix carcinoma. Neoplasma 42(1):21-24
27. Merino MJ, Jaffe G (1993) Age contrast in ovarian pathology. Cancer 71(Suppl 2):537-544
28. Miyake H, Hara I, Eto H (2004) Serum level of cathepsin B and its density in men with prostate cancer as novel markers of disease progression. Anticancer Res 24(4):2573-2577
29. Mulaomerovic A, Halilbasic A, Cickusic E, Zavasnik-Bergant T, Begic L, Kos J (2007) Cystatin C as a potential marker for relapse in patients with non-Hodgkin B-cell lymphoma. Cancer Lett 248(2):192-197
30. Nishida Y, Kohno K, Kawamata T, Morimitsu K, Kuwano M, Miyakawa I (1995) Increased cathepsin L levels in serum in some patients with ovarian cancer: comparison with CA125 and CA72-4. Gynecol Oncol 56(3):357-361
31. Nishikawa H, Ozaki Y, Nakanishi T, Blomgren K, Tada T, Arakawa A, Suzumori K (2004) The role of cathepsin B and cystatin C in the mechanisms of invasion by ovarian cancer. Gynecol Oncol 92(3):881-886
32. Pecorelli S, Benedet JL, Creasman WT, Shepherd JH (1999) FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet 65(3):243-249
33. Premzl A, Turk V, Kos J (2006) Intracellular proteolytic activity of cathepsin B is associated with capillary-like tube formation by endothelial cells in vitro. J Cell Biochem 97(6):1230-1240
34. Schwartz MK (1995) Tissue cathepsins as tumor markers. Clin Chim Acta 237(1-2):67-78
35. Scully RE (1995) Pathology of ovarian cancer precursors. J Cell Biochem Suppl 23:208-218
36. Servov SF, Scully RE, Sobin LH (1973) International histologic classification of tumors. No.9: histologic typing of ovarian tumors. World Health Organization, Geneva, 1973
37. Sloane BF, Moin K, Krepela E, Rozhin J (1990) Cathepsin B and its endogenous inhibitors: the role in tumor malignancy. Cancer Metastasis Rev 9(4):333-352
38. Stabuc B, Vrhovec L, Stabuc-Silih M, Cizej TE (2000) Improved prediction of decreased creatinine clearance by serum cystatin C: use in cancer patients before and during chemotherapy. Clin Chem 46(2):193-197
39. Strojan P, Budihna M, Smid L, Svetic B, Vrhovec I, Skrk J (2001) Cathepsin B and L and steWn A and B levels as serum tumor markers in squamous cell carcinoma of the head and neck. Neoplasma 48(1):66-71
40. Strojan P, Svetic B, Smid L, Kos J (2004) Serum cystatin C in patients with head and neck carcinoma. Clin Chim Acta 344(1-2):155-161
41. Turk B, Turk D, Turk V (2000) Lysosomal cysteine proteases: more than scavengers. Biochim Biophys Acta 1477(1-2):98-111
42. Warwas M, Haczynska H, Gerber J, Nowak M (1997) Cathepsin B-like activity as a serum tumour marker in ovarian carcinoma. Eur J Clin Chem Clin Biochem 35(4):301-304
43. Wells M (2004) Recent advances in endometriosis with emphasis on pathogenesis, molecular pathology, and neoplastic transformation. Int J Gynecol Pathol 23(4):316-320
44. Yano M, Hirai K, Naito Z, Yokoyama M, Ishiwata T, Shiraki Y, Inokuchi M, Asano G (2001) Expression of cathepsin B and cystatin C in human breast cancer. Surg Today 31(5):385-389
45. Zore I, Krasovec M, Cimerman N, Kuhelj R, Werle B, Nielsen HJ, Brunner N, Kos J (2001) Cathepsin B/cystatin C complex levels in sera from patients with lung and colorectal cancer. Biol Chem 382(5):805-810